Why the study?
Does intact digoxin antibody or its Fab fragment alter hemodynamics in experimental hypertensive rats?
Does intact digoxin antibody or its Fab fragment alter hemodynamics in experimental hypertensive rats?
The blood pressure-lowering effect of intact digoxin antibody in hypertensive rats is likely due to its Fc domain rather than neutralization of an endogenous digitalis-like factor.
Intact digoxin antibody lowers BP via Fc domain in rat model; challenges endogenous factor hypothesis and leaves open clinical relevance.
The effects of i.v. injection of intact digoxin antibody (0.3 mg/rat) and of its Fab fragment (40 mg/rat) on blood pressure, cardiac output and total peripheral resistance were measured in conscious spontaneously hypertensive and deoxycorticosterone hypertensive rats. In vitro findings showed that Fab fragment bound radio-labelled digoxin, digitoxin and ouabain more efficiently than did intact antibody. In vivo, Fab fragment prevented the increase of total peripheral resistance induced by i.v. injection digoxin. However, Fab fragment of digoxin antibody did not alter blood pressure, cardiac output or total peripheral resistance in normal and salt-loaded spontaneously hypertensive rats (SHR) in uraemic SHR and in deoxycorticosterone hypertensive rats. We confirmed that intact digoxin antibody--bearing Fc domains with complement activating properties--lowered blood pressure in SHR and in deoxycorticosterone hypertension. This was due to a decrease in total peripheral resistance. Our data suggest that a circulating endogenous digitalis-like factor is unlikely to be important in blood pressure regulation in salt-loaded hypertension in the rat.
No takes yet. Share an insight, caveat, or question.
Mann et al. (1987) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: